Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

The article underscores Immuron Ltd's strong and ongoing collaboration with the U.S. Department of Defense, highlighting multiple DOD-sponsored trials for its orally delivered polyclonal antibody products—IMM‑124 (used in Travelan®) and CampETEC—targeting travelers’ diarrhea and enteric pathogens such as ETEC and Campylobacter. In a notable 2022 milestone, Immuron received US$3.4 million in funding for Phase II studies of IMM‑124, and reported 36.4% protective efficacy against moderate‑to‑severe ETEC‑induced diarrhea and 66.7% efficacy against severe cases, significantly reducing IV fluid requirements, early antibiotic use, and adverse events versus placebo. The company plans to progress to Phase III trials following completion of Phase II. CampETEC is currently undergoing randomized, placebo‑controlled trials in up to 868 participants, with a further two Phase II studies in Campylobacter and ETEC anticipated thereafter.

Stocks Down Under: These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead